Format

Send to

Choose Destination
Interv Cardiol Clin. 2017 Jul;6(3):453-464. doi: 10.1016/j.iccl.2017.03.013. Epub 2017 Apr 26.

Renal Denervation to Modify Hypertension and the Heart Failure State.

Author information

1
Division of Cardiology, Interventional Cardiology and Endovascular Laboratory, Weill Cornell Medical College, New York Presbyterian Hospital, 520 East 70th street, New York, NY 10021, USA.
2
Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
3
Division of Cardiology, Interventional Cardiology and Endovascular Laboratory, Weill Cornell Medical College, New York Presbyterian Hospital, 520 East 70th street, New York, NY 10021, USA. Electronic address: dnf9001@med.cornell.edu.

Abstract

Sympathetic overactivation of renal afferent and efferent nerves have been implicated in the development and maintenance of several cardiovascular disease states, including resistant hypertension and heart failure with both reduced and preserved systolic function. With the development of minimally invasive catheter-based techniques, percutaneous renal denervation has become a safe and effective method of attenuating sympathetic overactivation. Percutaneous renal denervation, therefore, has the potential to modify and treat hypertension and congestive heart failure. Although future randomized controlled studies are needed to definitively prove its efficacy, renal denervation has the potential to change the way we view and treat cardiovascular disease.

KEYWORDS:

Renal artery ablation; Renal denervation; Renal sympathetic activation; Resistant hypertension

PMID:
28600097
DOI:
10.1016/j.iccl.2017.03.013

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center